Are there any biomarkers that might indicate who might be responders to atezolizumab/bevacizumab for HCC?

Topics: Medical Oncology • Liver and Pancreas Tumors • Hepatocellular Carcinoma • Journal Club ft. NEJM publications

ex. VEGFR2 expression, inflammatory signature, PDL1, etc.

Answer from: Medical Oncologist at Academic Institution

Not at this time. Some preliminary studies are being done as ad hoc at this point and was not pre specified before the IMbrave study launching

Comments

Medical Oncologist at University of Texas MD Anderson Cancer Center
Further studies are required for the value of PDL-...

Answer from: Medical Oncologist at Community Practice

At this point nothing simple. There was some data presented at AACR 2020 from the single arm study but it looked at signatures. There were interesting findings but not ready for clinical practice

Related Questions